Australia's largest stock trading and investment forum Australia's #1 stock forum

NSB

Click for more information

2.50%

3.9¢ neuroscientific biopharmaceuticals ltd

Potential 100 bagger Biotech missed by the market, page-1518

First 1518 Last

F18FDG

1,233 Posts.

178

07/09/22

14:33

Post #: 63567045

Originally posted by KingHoves: ↑
For reasons unknown to me the BOD have the support of our major shareholder McRae investments. McRae investments have nominee director Stephen Quantrill on the board, so they would be well informed. I have reached out to Matt twice with no response, he is not interested in engaging with me, I would be interested to hear if other shareholders have received responses to their questions.
My sentiment has changed with regard to management only - let me stress that management aside, the fundamentals of this stock are significantly undervalued. I agree that in regard to industry peers Matts salary would be regarded as reasonable, my issue is with his performance, his achievements to date do not warrant pocking over 1m is shareholder funds. In my opinion, Matt is a poor performing director. Let me elaborate on this with facts, here is a collation of company announcements since listing with planned trial start dates:
Date
Announcement
Indicated Date for Neurology Trial
Indicated Date for Glaucoma Trial
Comments
Link
1
25/07/2018
Prospectus
Q1 2019
Q1 2019
Phase 1a
https://hotcopper.com.au/threads/ann-prospectus.4322366/
2
12/09/2018
NSB presentation to Investors in Singapore
Q1 2019
Q1 2019
Phase 1a
https://hotcopper.com.au/threads/ann-nsb-presentation-to-investors-in-singapore.4425884/
3
27/11/2018
AGM address
Q2 2019
Q2 2019

https://hotcopper.com.au/threads/ann-agm-address.4552715/
4
04/02/2019
Investor Newsletter
Q3 2019
Q2 2019

https://hotcopper.com.au/threads/ann-investor-newsletter.4624805/
5
19/03/2019
Investor Presentation
Q3 2019
Q2 2019

https://hotcopper.com.au/threads/ann-investor-presentation.4679407/
6
11/06/2019
Investor Presentation
Q3 2019
Q4 2019

https://hotcopper.com.au/threads/ann-investor-presentation.4805485/
7
30/08/2019
Appendix 4E and Annual Report

we are excited to progress the technology into human trials at the conclusion of the safety and toxicology programs which are expected to complete shortly
https://hotcopper.com.au/threads/ann-appendix-4e-and-annual-report.4940143/
8
22/10/2019
NSB - Techknow Conference Presentation Oct 19
Q1 2020
Q1 2020

https://hotcopper.com.au/threads/ann-nsb-techknow-conference-presentation-oct-19.5025977/
9
17/11/2019
NSB - Company Update
Q2 2020
Q2 2020

https://hotcopper.com.au/threads/ann-nsb-company-update.5078518/
10
02/02/2020
NSB - Glaucoma Study Update

Success in this study will allow the Company to progress into testing EmtinB in glaucoma patients in clinical trials this year
https://hotcopper.com.au/threads/ann-nsb-glaucoma-study-update.5203966/
11
10/03/2020
Positive Results in Glaucoma Pig Model

The company is progressing the safety and toxicology program of EmtinB to be concluded this year with first human studies to be initiated later this year.
https://hotcopper.com.au/threads/ann-positive-results-in-glaucoma-pig-model.5276629/
12
20/04/2020
NSB Signs Manufacturing Agreement with Mitsubishi

future clinical programs, scheduled to begin in the second half of 2020.
https://hotcopper.com.au/threads/ann-nsb-signs-manufacturing-agreement-with-mitsubishi.5350144/
13
20/05/2020
Techknow Invest Webinar Presentation
Q4 2020
Q4 2020
Assuming no further disruptions to clinical trials due to COVID-19
https://hotcopper.com.au/threads/ann-techknow-invest-webinar-presentation.5404900/
14
25/08/2020
Westar Capital Investor Presentation
Q1 2021
Q1 2021
Assuming no further disruptions to clinical trials due to COVID-19
https://hotcopper.com.au/threads/ann-westar-capital-investor-presentation.5580431/
15
13/10/2020
BIO Investor Forum Presentation
Q2 2021
Q1 2021

https://hotcopper.com.au/threads/ann-bio-investor-forum-presentation.5682053/
16
30/04/2021
Appendix 4C - quarterly

In preparation for the Company’s transition from preclinical to clinical development in 2021, two key executive appointments were made during the quarter
https://hotcopper.com.au/threads/ann-appendix-4c-quarterly.6034154/
17
22/06/2021
NSB partners with Linear Research for Phase I Clinical Study

A Phase I ocular study in glaucoma patients is also planned for 2H 2021
https://hotcopper.com.au/threads/ann-nsb-partners-with-linear-research-for-phase-i-clinical-study.6122465/
18
23/06/2021
Gold Coast Investment Showcase Presentation
Q3 2021
Q4 2021

https://hotcopper.com.au/threads/ann-gold-coast-investment-showcase-presentation.6123575/
19
03/09/2021
NSB Receives R&D Advance & Overseas Finding

NeuroScientific is currently completing the final stages of its preclinical safety program in preparation for the commencement of a first-in-human Phase I clinical study of EmtinB™.
https://hotcopper.com.au/threads/ann-nsb-receives-r-d-advance-overseas-finding.6266252/
20
03/09/2022
Company Presentation
Q4 2021
Q1 2022

https://hotcopper.com.au/threads/ann-company-presentation.6267017/
21
26/10/2021
Company Presentation
Q1 2022
Q2 2022

https://hotcopper.com.au/threads/ann-company-presentation.6375821/
22
11/11/2021
Chairman's Address to Shareholders

Our Neurology non-clinical safety program is in the final stages of completion and the Company looks forward to finally transitioning the program into clinical development in the first quarter of 2022

I’m also proud to say that this year our ophthalmology pre-clinical program completed a number of pivotal safety studies with 3 months non-human primate studies on track to be finalised in the early part of 2022 and allowing us to progress our Glaucoma program into Phase I.
https://hotcopper.com.au/threads/ann-chairmans-address-to-shareholders.6416051/
23
18/11/2021
Investor Webinar Presentation
Q1 2022
H1 2022

https://hotcopper.com.au/threads/ann-investor-webinar-presentation.6430019/
24
02/12/2021
Investor Webinar Presentation
Q1 2022
H1 2022

https://hotcopper.com.au/threads/ann-investor-webinar-presentation.6464177/
25
23/12/2021
Positive off-target safety assessment of EmtinB

another major step towards achieving the landmark milestone of starting first-in-human Phase I studies in the first half of 2022.
https://hotcopper.com.au/threads/ann-positive-off-target-safety-assessment-of-emtinb.6508037/
26
07/02/22
Successful completion of key studies in lead up to Phase I

Having previously completed all necessary nonclinical safety studies for its neurology safety program, conducted in accordance with Good Laboratory Practice (GLP) standards as required, NeuroScientific is in the final stages of collating the data from nonclinical GLP toxicity studies to confirm the safety and tolerability of repeat doses of EmtinB™ in animals prior to commencement of first-in-human Phase I clinical studies. This data is expected to be reported in Q1 CY22
https://hotcopper.com.au/threads/ann-successful-completion-of-key-studies-in-lead-up-to-phase-i.6571814/
27
24/03/22
Company Presentation
H1 2022
H2 2022

https://hotcopper.com.au/threads/ann-company-presentation.6658289/

From going through the above I came to the conclusion, whilst acknowledging the effects on Covid19, that:
Matt and the BOD are incompetent and/or
Matt and the BOD have intentionally deceived shareholders with regards to start dates of trials

Let me also clarify a few things from my CPA studies
Directors primary duty is to shareholders - I do not feel well informed, do you?
Directors have a duty to act in good faith with the corporations best interests - why do they keep pushing out timelines, it comes across as unethical that every quarter they continue to push them back by a month - why so many delays?
Directors have a duty to remain informed about the company operations - is Matt incompetent? Some of the timelines he has put up over the last 4 years have been revised so quickly, if in fact he is acting ethically, how does he not know all that is required to start these trials in the indicated timeframe?

Until now, myself included, there has not been enough emphasis on management missing deadlines, we have become a part of the problem as we have allowed this to happen without holding management accountable. It is because of this I recommend the following to all shareholders who feel misled like myself, and who are unhappy with managements performance
contact management ([email protected] or + 61 8 6382 1805) and ask them for an explanation on why trials have not started, using any reference from the above table. For example, on 30/08/2019 they said they would progress the technology into human trials at the conclusion of the safety and toxicology programs which are expected to complete shortly - how is it possible that trials still haven't started 2.5 years later if we haven't been deceived or they are incompetent
VOTE NO to the remuneration report when it comes time to vote, I cannot stress how important this is

Stop accepting mediocrity. Fair enough if you think I am as much an idiot for investing in the company in the first place.
Expand
It would seem some of your objections to management capability are bearing fruit.

Much of the recent delay - referred to numerous times - is the safety data from the preclinical program. I am guessing toxicology is an issue that they have struggled with for years. They may have got the data as good as they could get it, submitted (because they have hospital ethics approval) and got tripped up by an attentive scientific review. All speculation. But a bad start to a commercialisation programme, whichever way you look at it.

NSB Price at posting: 9.4¢ Sentiment: None Disclosure: Not Held

0 Great analysis

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

IBG

Ironbark acquires two Mt Isa projects, notes 2,977 ppm copper at surface

RNX

Renegade uncovers large IOCG breccia system at QLD's Mongoose Deeps

AHK

Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4

There are more pages in this discussion • 1 more message in this thread...

First 1518 Last

Add NSB (ASX) to my watchlist

(20min delay)
Last 3.9¢		Change -0.001(2.50%)		Mkt cap ! $5.639M

Open	High	Low	Value	Volume
3.9¢	3.9¢	3.9¢	$1.755K	45K

Buyers (Bids)

No.	Vol.	Price($)
1	300000	3.7¢

Sellers (Offers)

Price($)	Vol.	No.
3.9¢	25184	2

View Market Depth

No.	Vol.	Price($)
1	300000	0.037
2	20181	0.036
2	278000	0.035
1	140000	0.031
1	33332	0.030

Price($)	Vol.	No.
0.039	25184	2
0.041	125000	1
0.042	27998	1
0.050	1086	1
0.051	75976	1

Last trade - 10.40am 02/07/2024 (20 minute delay)

NSB (ASX) Chart